BREAKING NEWS: PharmaLive: Elan and Biogen Idec Announce TYSABRI Update

CLICK HERE FOR COMPLETE STORYElan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced today that their ongoing safety evaluation of TYSABRI(R) (natalizumab) has led to a previously diagnosed case of malignant astrocytoma being reassessed as progressive multifocal leukoencephalopathy (PML), in a patient in an open label Crohn's disease clinical trial.